ArrowMark Colorado Holdings’s AbCellera Biologics ABCL Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.2M	Hold	4,105,095	–	–	1.34%	5
2026 Q1	$14.3M	Hold	4,105,095	–	–	0.38%	80
2025 Q4	$14M	Hold	4,105,095	–	–	0.31%	94
2025 Q3	$20.6M	Hold	4,105,095	–	–	0.38%	76
2025 Q2	$14.1M	Hold	4,105,095	–	–	0.25%	104
2025 Q1	$9.15M	Hold	4,105,095	–	–	0.15%	131
2024 Q4	$12M	Hold	4,105,095	–	–	0.16%	119
2024 Q3	$10.7M	Hold	4,105,095	–	–	0.14%	131
2024 Q2	$12.2M	Hold	4,105,095	–	–	0.14%	123
2024 Q1	$18.6M	Hold	4,105,095	–	–	0.21%	104
2023 Q4	$23.4M	Hold	4,105,095	–	–	0.26%	92
2023 Q3	$18.9M	Hold	4,105,095	–	–	0.23%	98
2023 Q2	$26.5M	Buy	+4,105,095	New	+$28M	0.29%	87

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ArrowMark Colorado Holdings's ABCL Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 4,105,095 shares worth $32.2M. The position accounts for 1.34% of the portfolio, ranked #5.

ArrowMark Colorado Holdings first reported a position in ABCL in Q2 2023 and has held it in 13 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

ArrowMark Colorado Holdings held 4,105,095 shares of AbCellera Biologics worth $32.2M as of Q2 2026.
ArrowMark Colorado Holdings left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up 1.34% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #5 holding.
ArrowMark Colorado Holdings first reported a position in AbCellera Biologics in Q2 2023 and has held it in 13 quarters since.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.